Write a PPCP note for a 74‑year‑old male with hypertension, hyperlipidemia, chronic heart failure (presumed HFrEF), atrial fibrillation, dementia, and Parkinson disease who presents with agitation, diffuse rash, bilateral hand swelling, right foot swelling, dry cough, rales, mild eosinophilia, slightly elevated procalcitonin, normal BNP, stable vital signs, eGFR ≈ 66 mL/min/1.73 m² (creatinine 1.16 mg/dL), and is currently taking amiodarone, losartan, quetiapine, docusate sodium, lubiprostone, polyethylene glycol, and senna.

PPCP Note: 74-Year-Old Male with Heart Failure, Hypertension, and Multimorbidity

COLLECT

Patient Characteristics

• Demographics: 74-year-old male, 59.8 kg (140 lb), BMI 23.3 kg/m²
• Allergies: No known drug allergies

Medical History

Active Conditions:

• Chronic heart failure (type not documented; presumed HFrEF based on presentation)
• Hypertension
• Hyperlipidemia
• Atrial fibrillation (on amiodarone)
• Dementia (oriented × 0-1)
• Parkinson disease
• Prior prostate surgery

Family History: Mother and father with hypertension and hyperlipidemia; mother with diabetes

Social History

• Former smoker (quit 36.6 years ago)
• Married, wife is primary caregiver
• No current alcohol or illicit drug use

Current Medications (Outpatient)

• Amiodarone 200 mg daily
• Losartan 25 mg daily
• Quetiapine 25 mg at 5 PM
• Docusate sodium 200 mg daily
• Lubiprostone 24 mcg twice daily
• Polyethylene glycol 17 g daily
• Senna 17.2 mg nightly

Presenting Symptoms

• Bilateral hand swelling and right foot swelling (2 weeks)
• Persistent dry cough (1 week)
• Diffuse body rash
• Agitation (admission reason)
• Unable to provide reliable history due to dementia

OBJECTIVE

Vital Signs (Recent 8 Hours)

• BP: 124/68 → 126/92 mmHg
• HR: 52 bpm (bradycardic) → 100 bpm
• RR: 18 breaths/min
• SpO₂: 94-96% on room air
• Temperature: 97.7-97.8°F

Physical Examination

• Mental Status: Oriented × 0-1, easily agitated with touch
• Cardiovascular: Regular rhythm, normal rate (variable)
• Pulmonary: Rales present (indicates volume overload)
• Extremities: Localized right foot swelling (1st metatarsal/proximal phalanx area, soft, fluid-filled appearance)
• Skin: Diffuse rash, warm, capillary refill <2 seconds

Laboratory Data

• Renal Function: Creatinine 1.16 mg/dL, eGFR 66 mL/min/1.73 m² (CKD Stage 2)
• Electrolytes: Na 139, K 4.2, Cl 108 (mildly elevated), CO₂ 26 mmol/L
• BNP: 108 pg/mL (normal ≤121 pg/mL) — notably normal despite clinical volume overload
• Troponin I: 4 ng/L (normal range 3-53 ng/L)
• CBC: WBC 6.19, Hgb 14.6, Hct 42.8, Platelets 214
• Differential: Eosinophils 21% (H), absolute eosinophil count 1.3 × 10³/mcL (H) — suggests drug reaction or allergic process
• Procalcitonin: 0.08 ng/mL (mildly elevated, <0.05 normal)
• Liver Function: Normal (ALT 24, AST 16, Alk Phos 49, Total Bili 0.68)
• TSH: 2.58 mIU/mL (euthyroid)

Imaging

• Chest X-ray: No acute cardiopulmonary process, no pleural effusion, no pulmonary edema
• Right Foot X-ray: No fracture; soft tissue swelling plantar/medial aspect

Pending Studies

• Echocardiogram (to determine LVEF and assess for HFrEF vs. HFpEF)
• CT chest/abdomen/pelvis
• CT brain
• Blood cultures × 2
• Respiratory pathogen panel

ASSESS

Primary Problem: Acute Decompensated Heart Failure with Volume Overload

This 74-year-old male presents with clinical heart failure exacerbation evidenced by bilateral extremity edema, persistent cough, and pulmonary rales, despite a paradoxically normal BNP. 1 The normal BNP (108 pg/mL) does not exclude heart failure in this context—BNP can be falsely normal in obesity (though BMI is 23.3), flash pulmonary edema, or early decompensation 1. The clinical examination (rales, peripheral edema, cough) takes precedence over biomarkers in this setting.

Critical Assessment Points:

1. Heart Failure Phenotype Unknown: Echocardiogram pending to determine HFrEF vs. HFpEF. This is essential because guideline-directed medical therapy (GDMT) differs substantially between phenotypes 1, 2.

2. Hemodynamic Instability: Variable heart rate (52-100 bpm) with bradycardia episodes likely related to amiodarone. BP currently stable (124-126 systolic) but at risk for hypotension with diuretic initiation 3.

3. Volume Overload: Clinical evidence (rales, bilateral hand swelling, right foot edema) warrants immediate diuretic therapy regardless of HF phenotype 1, 2.

4. Suboptimal HF Medication Regimen:

   • Currently on losartan 25 mg daily (low dose ARB)
   • Missing critical GDMT components: No beta-blocker, no aldosterone antagonist, no SGLT2 inhibitor 1, 2
   • If HFrEF confirmed: requires ARNI/ACEI/ARB + beta-blocker + aldosterone antagonist + SGLT2 inhibitor 1, 2
   • If HFpEF confirmed: requires ARNI + aldosterone antagonist + SGLT2 inhibitor in select patients 1, 4

5. Atrial Fibrillation Management: On amiodarone 200 mg daily. No documented anticoagulation (warfarin, DOAC) despite AFib—major stroke risk 5. CHA₂DS₂-VASc score ≥4 (age 74, HTN, CHF, prior stroke unknown) mandates anticoagulation unless contraindicated 5.

6. Drug-Related Complications:

   • Quetiapine 25 mg: FDA labeling warns of orthostatic hypotension, syncope, falls, and worsening heart failure in elderly patients with cardiovascular disease 3. Quetiapine should be used with particular caution in patients with heart failure or conditions predisposing to hypotension 3. Given dementia/agitation, consider non-pharmacologic interventions first or alternative agents with lower cardiovascular risk 6.
   • Eosinophilia (21%) with rash: Suggests drug hypersensitivity reaction. Differential includes losartan, amiodarone, quetiapine, or lubiprostone. Lubiprostone can cause syncope/hypotension 7.
   • Bradycardia (HR 52): Likely amiodarone-related. Will complicate beta-blocker initiation if HFrEF confirmed.

7. Renal Function: eGFR 66 mL/min (CKD Stage 2). Requires dose adjustments for renally cleared medications and close monitoring with RAAS inhibitor/diuretic titration 1.

8. Polypharmacy in Elderly with Multimorbidity: This patient exemplifies the challenges described in 6—multiple chronic conditions, cognitive impairment, and polypharmacy increase risk of adverse drug reactions, drug-drug interactions, and drug-disease interactions. The multidisciplinary team approach is essential 6.

Secondary Problems

Dementia/Parkinson Disease with Agitation:

• Quetiapine prescribed for behavioral symptoms but poses significant cardiovascular risks 3
• Cognitive impairment limits medication adherence and self-monitoring
• Requires caregiver education and support

Hypertension:

• BP currently 124-126/68-92 mmHg
• Target BP in HF patients: <130/80 mmHg per 2017 ACC/AHA guidelines 1, 8
• Current losartan dose (25 mg) is subtherapeutic for both HTN and HF 1

Diffuse Rash with Eosinophilia:

• Likely drug hypersensitivity reaction
• Dermatology consult pending
• Consider discontinuing potential offending agents

Right Foot Swelling:

• Soft tissue swelling without fracture
• Likely related to volume overload vs. localized cellulitis (procalcitonin mildly elevated)
• Monitor for infection

PLAN

Immediate Actions (Inpatient Management)

1. Diuresis for Volume Overload

Initiate furosemide 40 mg IV daily (already ordered) to address pulmonary congestion and peripheral edema 1, 2. Monitor daily weights, strict intake/output, and electrolytes (K, Na, Cr) every 1-2 days during diuresis 1. Target: resolution of rales, reduction in peripheral edema, improvement in dyspnea. Adjust dose based on response (may require 40-80 mg IV BID if inadequate diuresis).

2. Determine Heart Failure Phenotype

Obtain echocardiogram urgently to assess LVEF, chamber sizes, valvular function, and diastolic parameters. This will guide GDMT selection:

• If HFrEF (LVEF <40%): Initiate quadruple therapy (ARNI/ACEI/ARB + beta-blocker + aldosterone antagonist + SGLT2 inhibitor) 1, 2
• If HFpEF (LVEF ≥50%): Consider ARNI + aldosterone antagonist + SGLT2 inhibitor 1, 4

3. Address Bradycardia and Amiodarone

• Current HR 52-100 bpm (variable)
• Cardiology consult to evaluate amiodarone necessity for AFib rate/rhythm control
• If beta-blocker needed for HFrEF, may need to reduce/discontinue amiodarone to avoid excessive bradycardia 1
• Consider alternative rate control (digoxin) if beta-blocker contraindicated, though less preferred 9

4. Anticoagulation for Atrial Fibrillation

No anticoagulation documented despite AFib—this is a critical omission. CHA₂DS₂-VASc score ≥4 indicates ≥2% annual stroke risk, mandating anticoagulation 5. Initiate apixaban 5 mg BID (preferred DOAC over warfarin due to lower bleeding risk and no need for INR monitoring) 5. Dose-reduce to 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5 mg/dL (patient meets age and weight criteria). Assess fall risk and bleeding risk (HAS-BLED score), but anticoagulation benefits typically outweigh risks in AFib with HF 5.

5. Discontinue or Taper Quetiapine

Quetiapine poses significant risks in this elderly patient with heart failure, including orthostatic hypotension, syncope, falls, and potential HF exacerbation 3. FDA labeling explicitly warns against use in patients with cardiovascular disease 3. Taper quetiapine 25 mg to discontinuation over 1-2 weeks while implementing non-pharmacologic behavioral interventions (reorientation, structured environment, caregiver education). If pharmacologic management still required, consider lower-risk alternatives (e.g., low-dose trazodone 25 mg HS for sleep/agitation, though data limited in dementia).

6. Investigate and Manage Drug Hypersensitivity

• Eosinophilia (21%) with diffuse rash suggests drug reaction
• Hold lubiprostone (can cause syncope/hypotension per FDA label 7) and reassess need
• Dermatology consult for rash evaluation
• Monitor eosinophil count; consider corticosteroids if severe drug reaction confirmed

7. Optimize Constipation Management

• Currently on docusate, lubiprostone, polyethylene glycol, senna (excessive polypharmacy)
• Simplify regimen: Discontinue lubiprostone (hypotension risk 7). Continue polyethylene glycol 17 g daily + senna 17.2 mg PRN. Add scheduled senna if inadequate response.

Guideline-Directed Medical Therapy Titration (Post-Discharge)

Once HF phenotype confirmed and patient hemodynamically stable:

If HFrEF (LVEF <40%):

Initiate and rapidly uptitrate quadruple therapy 1, 2:

1. ARNI (Sacubitril/Valsartan) — PREFERRED over ACEi/ARB:

   • Start sacubitril/valsartan 24/26 mg BID (after discontinuing losartan with 36-hour washout)
   • Titrate to target 97/103 mg BID over 3-6 weeks 1, 2
   • Monitor BP, K, Cr at each titration
   • If ARNI not tolerated: Continue losartan but increase to target 150 mg daily 1

2. Beta-Blocker:

   • Challenge: Current bradycardia (HR 52) on amiodarone
   • Strategy: Reduce/discontinue amiodarone first (cardiology input), then initiate carvedilol 3.125 mg BID or metoprolol succinate 12.5-25 mg daily
   • Titrate to target doses (carvedilol 25 mg BID, metoprolol succinate 200 mg daily) over 8-12 weeks 1
   • Monitor HR (target 50-60 bpm), BP, HF symptoms

3. Aldosterone Antagonist:

   • Start spironolactone 12.5-25 mg daily (if K <5.0, Cr <2.5 mg/dL)
   • Titrate to 25-50 mg daily 1
   • Monitor K, Cr closely (risk of hyperkalemia with RAAS inhibition + CKD)

4. SGLT2 Inhibitor:

   • Start dapagliflozin 10 mg daily or empagliflozin 10 mg daily (regardless of diabetes status) 2, 10
   • Reduces mortality and HF hospitalization 2
   • Monitor for volume depletion, genital mycotic infections

5. Additional Therapies (if indicated):

   • Digoxin 0.125 mg daily: Consider if persistent symptoms despite GDMT, especially with AFib for rate control 9. Monitor digoxin level (target 0.5-0.9 ng/mL), renal function.
   • Hydralazine/Isosorbide Dinitrate: Not first-line unless patient is Black with persistent NYHA III-IV symptoms on GDMT 1.
   • Ivabradine: If HR >70 bpm on maximally tolerated beta-blocker and sinus rhythm (not applicable with AFib) 1.
   • Vericiguat: Consider if recent HF hospitalization and elevated natriuretic peptides 2.

If HFpEF (LVEF ≥50%):

Initiate targeted therapy 1, 4:

1. SGLT2 Inhibitor: Dapagliflozin 10 mg daily or empagliflozin 10 mg daily 4
2. ARNI: Sacubitril/valsartan 24/26 mg BID, titrate to 97/103 mg BID 4
3. Aldosterone Antagonist: Spironolactone 12.5-25 mg daily (if K <5.0) 4
4. Diuretics: Continue as needed for volume management 1

Note: Evidence for HFpEF therapies is less robust than HFrEF, but recent trials support SGLT2i and ARNI 4.

Monitoring Parameters

Efficacy:

• Daily weights (target: return to dry weight, typically 1-2 kg loss during diuresis)
• Symptoms: Resolution of dyspnea, cough, orthopnea, peripheral edema
• Functional status: NYHA class improvement
• Rales on lung exam: Should resolve with diuresis

Safety:

• Renal function: Cr, eGFR every 1-2 days during diuresis, then weekly during GDMT titration. Acceptable Cr increase up to 0.3 mg/dL or 30% from baseline with RAAS inhibitors 1.
• Electrolytes: K, Na every 1-2 days during diuresis, then weekly. Hold aldosterone antagonist if K >5.5 mmol/L 1.
• Blood pressure: Daily during hospitalization, at each outpatient visit. Target <130/80 mmHg but tolerate SBP 90-130 mmHg if asymptomatic 1, 10, 11. Avoid SBP <90 mmHg (associated with worse outcomes in HF) 10.
• Heart rate: Daily. Target 50-60 bpm on beta-blocker (if HFrEF). Hold beta-blocker if HR <50 bpm and symptomatic 1.
• Volume status: Daily weights, I/O, edema assessment
• Eosinophil count: Repeat in 3-5 days to assess drug reaction resolution
• Digoxin level: If initiated, check 1-2 weeks after starting (target 0.5-0.9 ng/mL) 9

Patient and Caregiver Education

Given severe dementia (oriented × 0-1), education must focus on wife/caregiver:

1. Heart Failure Basics:

   • HF is a chronic condition requiring lifelong medication adherence
   • Symptoms to monitor: shortness of breath, swelling, weight gain, fatigue, cough

2. Daily Self-Monitoring:

   • Weigh patient daily at same time (morning, after urination, before eating)
   • Call provider if weight increases >2-3 lb in 1 day or >5 lb in 1 week 1
   • Monitor for worsening dyspnea, increased edema, orthopnea

3. Dietary Modifications:

   • Sodium restriction <2 g/day (1500 mg ideal) 1
   • Avoid high-sodium foods (processed meats, canned soups, fast food, salty snacks)
   • Fluid restriction 1.5-2 L/day if hyponatremia or severe HF 1

4. Medication Administration:

   • Importance of adherence: Missing doses increases hospitalization risk
   • Timing: Take medications at same time daily (use pill organizer)
   • Diuretics: Take in morning to avoid nocturia
   • ARNI/ACEi/ARB: Take with or without food; report dizziness, lightheadedness
   • Beta-blocker: Do not stop abruptly (risk of rebound tachycardia, ischemia)
   • Anticoagulation (apixaban): Take exactly as prescribed; report bleeding, falls

5. Adverse Effects to Report:

   • Dizziness, lightheadedness, syncope: May indicate hypotension or bradycardia
   • Worsening confusion, falls: May indicate medication side effects
   • Rash, itching: Drug reaction
   • Cough (new or worsening): ACEi side effect (switch to ARB/ARNI if intolerable)
   • Hyperkalemia symptoms: Muscle weakness, palpitations (rare but serious)

6. Lifestyle Modifications:

   • Exercise: Encourage light activity as tolerated (short walks) to prevent deconditioning 1
   • Avoid NSAIDs: Worsen HF and renal function 1
   • Limit alcohol: ≤1 drink/day or abstain 1
   • Smoking cessation: Already quit (reinforce maintenance)

7. When to Seek Emergency Care:

   • Severe shortness of breath at rest
   • Chest pain
   • Syncope or near-syncope
   • Confusion worse than baseline
   • Significant bleeding (if on anticoagulation)

Referrals and Follow-Up

1. Cardiology/HF Specialist:

   • Urgent consult during hospitalization for GDMT initiation and amiodarone management
   • Outpatient follow-up in 1-2 weeks post-discharge for medication titration
   • Consider advanced HF therapies if refractory symptoms (ICD, CRT if HFrEF with QRS ≥150 ms) 1

2. Electrophysiology:

   • If HFrEF with LVEF ≤35% and QRS ≥150 ms: CRT-D (cardiac resynchronization therapy with defibrillator) for secondary prevention of sudden cardiac death 1
   • If HFrEF with LVEF ≤35% on optimal medical therapy ≥3 months: ICD for primary prevention 1

3. Neurology:

   • Consult pending for dementia/Parkinson management
   • Optimize non-pharmacologic behavioral interventions to minimize psychotropic use

4. Dermatology:

   • Consult pending for rash evaluation and drug hypersensitivity assessment

5. Dietitian:

   • Referral for sodium restriction counseling (target <2 g/day) 1
   • Provide caregiver with low-sodium meal plans and food lists

6. Pharmacist:

   • Medication reconciliation to simplify regimen and reduce polypharmacy 6
   • Review for drug-drug interactions (amiodarone interacts with digoxin, warfarin, many others)
   • Provide caregiver education on medication administration

7. Social Work/Case Management:

   • Assess home safety (fall risk with dementia, Parkinson, potential orthostatic hypotension)
   • Evaluate caregiver burden and need for home health services
   • Ensure access to medications (insurance coverage, financial assistance programs)

8. Primary Care Provider:

   • Follow-up within 7 days of discharge for vital signs, weight, symptom assessment
   • Labs (Cr, K, Na) within 3-5 days of discharge after diuretic/GDMT changes
   • Ongoing monitoring every 1-2 weeks during GDMT titration, then monthly once stable

Discharge Planning

Expected discharge [DAY_OF_WEEK] pending:

• Resolution of volume overload (rales, edema)
• Hemodynamic stability (BP >90/60 mmHg, HR 50-100 bpm)
• Echocardiogram completed with GDMT initiated
• Caregiver education completed
• Outpatient follow-up appointments scheduled

Discharge Medications (Anticipated):

• Furosemide 40 mg PO daily (adjust based on response)
• Sacubitril/valsartan 24/26 mg BID (or losartan 50 mg daily if ARNI not tolerated)
• Carvedilol 3.125 mg BID (or metoprolol succinate 25 mg daily) — if bradycardia resolves
• Spironolactone 12.5-25 mg daily (if K <5.0)
• Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
• Apixaban 2.5-5 mg BID (dose based on age/weight/Cr)
• Amiodarone 200 mg daily (pending cardiology input; may discontinue)
• Polyethylene glycol 17 g daily
• Senna 17.2 mg PRN constipation
• Discontinue: Quetiapine, lubiprostone, docusate (redundant)

IMPLEMENT

Inpatient Actions (Days 1-3)

Day 1:

• Furosemide 40 mg IV daily initiated
• Strict I/O, daily weights
• Labs: Cr, K, Na daily
• Echocardiogram ordered (STAT)
• Cardiology consult for GDMT and amiodarone management
• Neurology consult for dementia/Parkinson
• Dermatology consult for rash
• Hold quetiapine (taper plan)
• Hold lubiprostone
• Initiate apixaban 2.5 mg BID (meets dose-reduction criteria: age 74, weight 59.8 kg)

Day 2:

• Assess diuresis response (weight loss, symptom improvement, rales resolution)
• Review echocardiogram results → determine HFrEF vs. HFpEF
• Cardiology recommendations for GDMT initiation
• Labs: Cr, K, Na
• Caregiver education session #1 (HF basics, daily weights, sodium restriction)

Day 3:

• Continue diuresis if needed (adjust furosemide dose)
• Initiate GDMT based on HF phenotype:
  • If HFrEF: Start sacubitril/valsartan 24/26 mg BID (discontinue losartan), carvedilol 3.125 mg BID (if HR >55 bpm), spironolactone 12.5 mg daily (if K <5.0), dapagliflozin 10 mg daily
  • If HFpEF: Start sacubitril/valsartan 24/26 mg BID, spironolactone 12.5 mg daily, dapagliflozin 10 mg daily
• Labs: Cr, K, Na
• Caregiver education session #2 (medication administration, adverse effects, when to call)

Day 4-5 (Discharge Day):

• Confirm volume overload resolved (no rales, reduced edema, weight stable)
• Hemodynamically stable (BP >90/60 mmHg, HR 50-100 bpm)
• Labs: Cr, K, Na within acceptable range
• Discharge prescriptions provided
• Caregiver education completed (written materials, teach-back method)
• Follow-up appointments scheduled:
  • PCP in 7 days
  • Cardiology in 1-2 weeks
  • Labs (Cr, K, Na) in 3-5 days
• Home health referral for medication management and vital sign monitoring

Outpatient Titration (Weeks 1-12)

Week 1 (Post-Discharge):

• PCP visit: Vital signs, weight, symptom assessment
• Labs: Cr, K, Na (assess for hyperkalemia, worsening renal function)
• Adjust diuretic dose based on volume status

Weeks 2-4:

• Cardiology visit: Uptitrate GDMT
  • Sacubitril/valsartan 24/26 mg BID → 49/51 mg BID (if BP tolerates)
  • Carvedilol 3.125 mg BID → 6.25 mg BID (if HR >55 bpm, no symptomatic hypotension)
  • Spironolactone 12.5 mg daily → 25 mg daily (if K <5.0)
• Labs: Cr, K, Na 3-5 days after each titration

Weeks 6-8:

• Cardiology visit: Continue GDMT uptitration
  • Sacubitril/valsartan 49/51 mg BID → 97/103 mg BID (target dose)
  • Carvedilol 6.25 mg BID → 12.5 mg BID → 25 mg BID (target dose)
• Labs: Cr, K, Na after each titration

Weeks 10-12:

• Cardiology visit: Assess for additional therapies
  • If persistent symptoms (NYHA III-IV): Consider digoxin 0.125 mg daily, ivabradine (if sinus rhythm, HR >70 bpm), or vericiguat
  • If HFrEF with LVEF ≤35%, QRS ≥150 ms: Refer to electrophysiology for CRT-D
• Labs: Cr, K, Na, digoxin level (if initiated)

Ongoing (Every 3-6 Months):

• PCP/Cardiology visits: Vital signs, weight, symptom assessment, medication adherence
• Labs: Cr, K, Na, BNP/NT-proBNP (trend over time)
• Echocardiogram annually to reassess LVEF and cardiac remodeling
• Adjust medications as needed based on clinical status

Adherence Strategies

Given dementia and caregiver dependence:

• Pill organizer: Weekly setup by caregiver or home health nurse
• Medication administration record: Caregiver logs each dose
• Simplify regimen: Once-daily dosing when possible (e.g., metoprolol succinate vs. carvedilol BID)
• Pharmacy coordination: Use single pharmacy for all medications; request blister packs if available
• Home health visits: Weekly initially for medication supervision, vital signs, weight monitoring
• Motivational interviewing: Emphasize to caregiver the mortality/hospitalization benefits of GDMT adherence 1, 2

FOLLOW-UP: MONITOR AND EVALUATE

Short-Term Goals (1-3 Months)

1. Resolution of HF symptoms:

   • No dyspnea at rest or with minimal exertion
   • No orthopnea or paroxysmal nocturnal dyspnea
   • No peripheral edema or rales
   • Weight stable at dry weight

2. GDMT uptitration to target doses:

   • Sacubitril/valsartan 97/103 mg BID (or losartan 150 mg daily)
   • Carvedilol 25 mg BID (or metoprolol succinate 200 mg daily)
   • Spironolactone 25-50 mg daily
   • Dapagliflozin 10 mg daily or empagliflozin 10 mg daily

3. Hemodynamic stability:

   • BP 90-130/60-80 mmHg (avoid SBP <90 or >140 mmHg) 10, 11
   • HR 50-70 bpm (if HFrEF on beta-blocker)
   • No symptomatic hypotension or bradycardia

4. Renal function and electrolytes stable:

   • Cr ≤1.5 mg/dL (acceptable increase up to 0.3 mg/dL from baseline)
   • K 4.0-5.0 mmol/L (hold aldosterone antagonist if >5.5 mmol/L)
   • Na 135-145 mmol/L

5. Anticoagulation for AFib:

   • Apixaban 2.5-5 mg BID continued
   • No bleeding complications
   • No stroke/TIA events

6. Medication adherence:

   • Caregiver reports >90% adherence
   • No missed doses or medication errors

Long-Term Goals (6-12 Months)

1. Functional status improvement:

   • NYHA class I-II (minimal symptoms with ordinary activity)
   • Able to perform activities of daily living with minimal assistance
   • No HF hospitalizations

2. Cardiac remodeling (if HFrEF):

   • Repeat echocardiogram at 6-12 months
   • Improvement in LVEF (goal: increase by ≥5-10%)
   • Reduction in LV end-diastolic diameter
   • Improvement in diastolic function

3. Quality of life:

   • Reduced caregiver burden
   • Patient able to participate in light activities (short walks, social interactions)
   • No falls or injuries related to medications

4. Mortality and morbidity reduction:

   • No cardiovascular death
   • No HF hospitalizations
   • No stroke/TIA (with anticoagulation)

Red Flags Requiring Urgent Reassessment

• Worsening HF symptoms: Increased dyspnea, orthopnea, edema, weight gain >2-3 lb in 1 day
• Hypotension: SBP <90 mmHg with dizziness, syncope, or altered mental status
• Bradycardia: HR <50 bpm with symptoms (dizziness, fatigue, syncope)
• Hyperkalemia: K >5.5 mmol/L (hold aldosterone antagonist, recheck in 3-5 days)
• Worsening renal function: Cr increase >0.5 mg/dL or >50% from baseline (hold RAAS inhibitors, reassess volume status)
• Bleeding: Any significant bleeding on anticoagulation (hold apixaban, seek emergency care)
• Falls: Increased fall frequency (reassess medications, home safety)
• Acute decompensation: Severe dyspnea, hypoxia, pulmonary edema (call 911, hospital admission)

Pitfalls to Avoid

1. Undertreating HF due to "normal" BNP: Clinical exam trumps biomarkers. This patient has clear volume overload despite BNP 108 pg/mL 1.

2. Delaying GDMT initiation: Start all four drug classes simultaneously (if HFrEF) and uptitrate rapidly—do not wait for one drug to reach target before starting another 2.

3. Stopping RAAS inhibitors for mild Cr elevation: Acceptable Cr increase up to 0.3 mg/dL or 30% from baseline. Only hold if Cr increases >0.5 mg/dL or >50%, or if K >5.5 mmol/L 1.

4. Avoiding beta-blockers due to bradycardia: Address amiodarone first (reduce/discontinue), then initiate beta-blocker cautiously. Beta-blockers are essential for HFrEF mortality reduction 1.

5. Continuing quetiapine despite cardiovascular risks: FDA labeling explicitly warns against use in HF patients 3. Prioritize non-pharmacologic interventions for dementia-related agitation 6.

6. Omitting anticoagulation in AFib: This patient has no documented anticoagulation despite AFib and HF—a major stroke risk. Initiate DOAC immediately 5.

7. Ignoring polypharmacy in elderly with multimorbidity: Simplify regimen, discontinue unnecessary medications (lubiprostone, docusate, quetiapine), and involve pharmacist for medication reconciliation 6.

8. Inadequate caregiver education: Given severe dementia, caregiver is responsible for all medication administration and symptom monitoring. Ensure comprehensive education with teach-back method 1.

9. Lack of multidisciplinary coordination: HF management in elderly with multimorbidity requires coordinated care between cardiology, PCP, neurology, pharmacy, dietitian, and social work 6.

10. Failing to reassess goals of care: In elderly patients with advanced dementia and multiple comorbidities, discuss goals of care with caregiver. If comfort-focused care preferred, aggressive GDMT uptitration may not align with patient/family values 6, 12.

---

This PPCP note prioritizes evidence-based HF management while addressing the complexities of polypharmacy, multimorbidity, and cognitive impairment in an elderly patient. The plan emphasizes rapid GDMT initiation, medication safety, caregiver education, and multidisciplinary coordination to optimize outcomes.